The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cogent Biosciences Inc shares valued at $332,412 were purchased by Pinnow Cole on Jan 14 ’25. At $7.60 per share, Pinnow Cole acquired 43,750 shares. The insider’s holdings grew to 45,848 shares worth approximately $0.41 million following the completion of this transaction.
As published in a research note from Needham on December 11, 2024, Cogent Biosciences Inc [COGT] has been rated down from a Buy to a Hold. Analysts at Robert W. Baird downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in late February. As of February 08, 2024, Citigroup has initiated its “Buy” rating for COGT. Earlier on December 11, 2023, Wedbush downgraded its rating. Their new recommendation was “a Neutral” for COGT stock which previously was a “an Outperform”.
Analyzing COGT Stock Performance
During the last five days, there has been a surge of approximately 9.48%. Over the course of the year, Cogent Biosciences Inc shares have jumped approximately 13.97%. Shares of the company reached a 52-week high of $9.03 on 01/23/25 and a 52-week low of $6.60 on 01/13/25. A 50-day SMA is recorded $8.65, while a 200-day SMA reached $9.09. Nevertheless, trading volume fell to 2.22 million shares from 1.02 million shares the previous day.
Support And Resistance Levels for Cogent Biosciences Inc (COGT)
According to the 24-hour chart, there is a support level at 8.18, which, if violated, would cause prices to drop to 7.48. In the upper region, resistance lies at 9.31. The next price resistance is at 9.74. RSI (Relative Strength Index) is 61.02 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.40, which suggests the price will decrease in the coming days. Percent R is at 5.76%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
